<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13497">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02931214</url>
  </required_header>
  <id_info>
    <org_study_id>GMI-1359-101</org_study_id>
    <nct_id>NCT02931214</nct_id>
  </id_info>
  <brief_title>Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1359 in Healthy Volunteers</brief_title>
  <official_title>A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GMI-1359 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlycoMimetics Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celerion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlycoMimetics Incorporated</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety and pharmacokinetics of single ascending IV
      doses of GMI-1359 in healthy adult subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, single ascending IV dose study
      conducted at one study center in the United States. Safety will be assessed throughout the
      study and serial blood samples and urine samples will be collected for the safety and
      pharmacokinetic assessment of GMI-1359.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment related adverse events</measure>
    <time_frame>15 days</time_frame>
    <description>Treatment related adverse events as a measure of safety and tolerability of GMI-1359</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>48 hours</time_frame>
    <description>Cmax (peak plasma concentration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>48 hours</time_frame>
    <description>AUC (area under the curve)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>48 hours</time_frame>
    <description>Tmax (time to peak plasma concentration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>48 hours</time_frame>
    <description>CD34 cell measurement</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>GMI-1359</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GMI-1359</intervention_name>
    <arm_group_label>GMI-1359</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adult male or females, 19-60 years of age (inclusive).

          2. Medically healthy with no clinically significant screening results.

          3. Females of childbearing potential must either be sexually inactive (abstinent) for 3
             months prior to dosing or be using an acceptable birth control method

          4. Females must have a negative pregnancy test at the time of screening and prior to
             dosing for inclusion in the study.

          5. Understands the study procedures in the informed consent form, and be willing and
             able to comply with the protocol.

        Exclusion Criteria:

          1. Subject is mentally or legally incapacitated.

          2. History of any illness that, in the opinion of the PI, might confound the results of
             the study or poses an additional risk to the subjects by their participation in the
             study.

          3. Normal clinical laboratory values.

          4. Normal heart rate and blood pressure.

          5. Blood donation or significant blood loss within 56 days prior to dosing.

          6. Plasma donation within 7 days prior to dosing.

          7. Participation in another clinical trial within 28 days prior to dosing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Sterling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Celerion</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Sterling, MD</last_name>
    <phone>402-476-2811</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Sterling, MD</last_name>
      <phone>402-476-2811</phone>
    </contact>
    <investigator>
      <last_name>Laura Sterling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 10, 2016</lastchanged_date>
  <firstreceived_date>September 6, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Subjects</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
